The use of pharmacogenetics to increase the safety of colorectal cancer patients treated with fluoropyrimidines [0.03%]
药物基因组学在氟尿嘧啶类药物治疗结直肠癌安全性中的应用
Elena De Mattia,Rossana Roncato,Chiara Dalle Fratte et al.
Elena De Mattia et al.
Fluoropyrimidines (FP) are given in the combination treatment of the advanced disease or as monotherapy in the neo-adjuvant and adjuvant treatment of colorectal cancerand other solid tumors including breast, head and neck and gastric cancer...
Pharmacogenetics implementation in the clinics: information and guidelines for germline variants [0.03%]
临床实践中的药物基因组学应用：关于胚系变异的信息和指南
Gladys Olivera,Luis Sendra,María José Herrero et al.
Gladys Olivera et al.
The aim of this work was to supply an overview of the germline Pharmacogenetics that can be already implemented in the oncology clinical practice. An explanation of the three pillars considered necessary for determining which genetic polymo...
Cyclin-dependent kinase inhibitors in brain cancer: current state and future directions [0.03%]
脑癌中周期素依赖性激酶抑制剂的现状和未来方向
Viktorija Juric,Brona Murphy
Viktorija Juric
Cyclin-dependent kinases (CDKs) are important regulatory enzymes in the normal physiological processes that drive cell-cycle transitions and regulate transcription. Virtually all cancers harbour genomic alterations that lead to the constitu...
Circulating tumor cells and drug history in primary breast cancer patients [0.03%]
原发性乳腺癌患者中的循环肿瘤细胞和既往用药史
Silvia Jurisova,Marián Karaba,Gabriel Minarik et al.
Silvia Jurisova et al.
Aim: Different types of chronic medication may affect breast cancer prognosis. Circulating tumor cells (CTCs) play an important role in cancer metastasis formation. There is no evidence of how chronic medication affects CTCs and breast canc...
Predictive value of exosomes and their cargo in drug response/resistance of breast cancer patients [0.03%]
外泌体及其负载物对乳腺癌患者药物反应/抗性的预测价值
Heidi Schwarzenbach,Peter B Gahan
Heidi Schwarzenbach
Exosomes are small extracellular vesicles engaged in intercellular communication in both healthy and tumor cells. When released by the primary tumor, they transfer their cargo including nucleic acids, proteins, and lipids to target cells, t...
Detection of circulating tumor cells in blood of pancreatic ductal adenocarcinoma patients [0.03%]
胰腺导管腺癌患者血液循环肿瘤细胞的检测
Andrea Mayado,Alberto Orfao,Anouk Mentink et al.
Andrea Mayado et al.
Aim: Previous studies suggest that circulating tumor cells (CTC) are present at very low frequencies in blood of pancreatic cancer (PC) patients. However, no technique has proven efficient for their detection, in part due to the lack of acc...
Moammir H Aziz,Aamir Ahmad
Moammir H Aziz
Bini Chhetri Soren,Jagadish Babu Dasari,Alessio Ottaviani et al.
Bini Chhetri Soren et al.
DNA topoisomerase I enzymes relieve the torsional strain in DNA; they are essential for fundamental molecular processes such as DNA replication, transcription, recombination, and chromosome condensation; and act by cleaving and then religat...
How to conjugate the stemness marker ALDH1A1 with tumor angiogenesis, progression, and drug resistance [0.03%]
醛脱氢酶1A1与肿瘤血管生成、进展及药物抗性之间的关系研究
Valerio Ciccone,Lucia Morbidelli,Marina Ziche et al.
Valerio Ciccone et al.
Cancer is the second leading cause of death worldwide. The survival of cancer patients depends on the efficacy of therapies and the development of resistance. There are many mechanisms involved in the acquisition of drug resistance by cance...
Tara Hyder,Juan Luis Gomez Marti,Azadeh Nasrazadani et al.
Tara Hyder et al.
Most breast cancers are hormone-receptor positive (HR+). However, more women eventually die from HR+ breast cancer than from either HER2+ or triple negative breast cancer. Endocrine therapies continue to be the mainstay of treatment. In 40%...